Novartis AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes
- First Posted Date
- 2009-01-14
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 338
- Registration Number
- NCT00821977
- Locations
- 🇨🇦
G.A. Research Associates Moncton, New Brunswick E1G 1 A7, Moncton, New Brunswick, Canada
🇺🇸AM Diabetes and Endocrinology Center, Bartlett, Tennessee, United States
🇺🇸Ozark Medical-Surgical Associates, Ltd., Springfield, Missouri, United States
Efficacy of add-on Therapy With Vildagliptin in Chinese Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2009-01-14
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 404
- Registration Number
- NCT00822211
- Locations
- 🇨🇳
The General Hospital of the PLA, Beijing, China
🇨🇳Guangdong Provincial People's Hospital, Guangzhou, China
🇨🇳Second Affiliated Hospital of Nanchang University, Nanchang, China
Reducing the Overall Risk Level in Patients Suffering From Metabolic Syndrome
- Conditions
- Hypertension, Dyslypidaemia
- Interventions
- First Posted Date
- 2009-01-13
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 144
- Registration Number
- NCT00821574
A Comparative Study of the Efficacy of Penciclovir 10mg/g (1%) Cream in Preventing the Appearance of Classical Lesion in Recurrent Cold Sore Sufferers
- First Posted Date
- 2009-01-12
- Last Posted Date
- 2012-04-20
- Lead Sponsor
- Novartis
- Target Recruit Count
- 126
- Registration Number
- NCT00820534
- Locations
- 🇬🇧
Belfast Health and Social Care Trust, Royal Victoria Hospital, Belfast, United Kingdom
Efficacy and Safety of Aliskiren in Patients With Mild to Moderate Hypertension During Exercise
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2009-01-09
- Last Posted Date
- 2011-06-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 68
- Registration Number
- NCT00819767
- Locations
- 🇬🇧
Investigative Site, Leicester, United Kingdom
A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant Hypertension
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2009-01-06
- Last Posted Date
- 2021-06-02
- Lead Sponsor
- Novartis
- Target Recruit Count
- 155
- Registration Number
- NCT00817635
- Locations
- 🇺🇸
Horizon Research Group, Inc, Mobile, Alabama, United States
🇺🇸Northwest Clinical Trials, Boise, Idaho, United States
🇺🇸KRK Medical Research, Dallas, Texas, United States
A Study to Evaluate the Effects of LCI699 on Cortisol in Participants With Hypertension
- First Posted Date
- 2009-01-06
- Last Posted Date
- 2021-06-02
- Lead Sponsor
- Novartis
- Target Recruit Count
- 63
- Registration Number
- NCT00817414
- Locations
- 🇺🇸
Impact Clinical Trials, Beverly Hills, California, United States
🇺🇸Long Beach Center for Clinical Research, Long Beach, California, United States
🇺🇸Innovative Clinical Research, Inc, Harbor City, California, United States
Efficacy, Safety and Pharmacokinetics of QAV680 in Asthma Patients
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2008-12-24
- Last Posted Date
- 2017-03-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 37
- Registration Number
- NCT00814216
- Locations
- 🇮🇳
Novartis Investigative Site, Mysore, India
🇮🇳Novartis Investigative SIte, Nagpur, India
8 Weeks Study to Evaluate the Efficacy and Safety of Valsartan in Combination With Aliskiren Compared to Valsartan Alone in Patients With Stage 2 Hypertension
- First Posted Date
- 2008-12-17
- Last Posted Date
- 2011-05-02
- Lead Sponsor
- Novartis
- Target Recruit Count
- 451
- Registration Number
- NCT00809926
- Locations
- 🇺🇸
Sites in USA, East Hanover, New Jersey, United States
Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants
- Conditions
- Meningococcal InfectionMeningitis
- Interventions
- Biological: MenACWY-CRM197Biological: DTaP (Diptheria, Tetanus, Pertussis) VaccineBiological: Hib (Haemophilus influenza b) VaccineBiological: IPV (Inactivated Polio Vaccine) VaccineBiological: Pneumococcal conjugate VaccineBiological: MMR (Measles, Mumps, and Rubella) VaccineBiological: Varicella VaccineBiological: Hepatitis A Virus
- First Posted Date
- 2008-12-10
- Last Posted Date
- 2013-07-09
- Lead Sponsor
- Novartis
- Target Recruit Count
- 7744
- Registration Number
- NCT00806195
- Locations
- 🇺🇸
67 Madera Family Medical Group 1111 West 4th Street, Madera, California, United States
🇺🇸110 Pediatric Alliance Southwestern - Squirrel Hill 4070 Beechwood Blvd, Pittsburgh, Pennsylvania, United States
🇺🇸112 Pediatric Alliance, Southwestern 850 Clairton Blvd, Pittsburgh, Pennsylvania, United States